SCHEDULE: P. Kent Hawryluk Boosts MBX Biosciences Stake to 4.3%
Beneficial Ownership Disclosure
P. Kent Hawryluk reported beneficial ownership of 4.3% of MBX Biosciences, Inc. common stock, totaling 1,995,759 shares.
Summary
- P. Kent Hawryluk beneficially owns 1,995,759 shares of MBX Biosciences, Inc. Common Stock.
- This represents 4.3% of the company's outstanding common stock.
- The ownership includes 481,397 shares held directly by the Reporting Person.
- It also includes 1,066,085 shares issuable upon exercise of stock options exercisable within 60 days of September 30, 2025.
- Additionally, 448,277 shares are held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, for which the Reporting Person serves as trustee.
- The percentage of class was calculated based on 44,902,302 shares of Common Stock outstanding as of November 3, 2025, plus the 1,066,085 shares from exercisable stock options.
Sentiment
Score: 7
Explanation: The filing indicates a substantial beneficial ownership by P. Kent Hawryluk, including a significant portion from exercisable stock options. This level of insider ownership can be viewed positively as it aligns management's interests with those of other shareholders and suggests confidence in the company's future.
Positives
- Significant beneficial ownership by P. Kent Hawryluk, indicating alignment of interests with shareholders.
- A substantial portion of the ownership comes from exercisable stock options, suggesting potential long-term commitment and confidence in the company's future value.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure of a significant individual shareholder's stake. It does not provide broader industry context or trends.
Related Party Transactions
- P. Kent Hawryluk, the Reporting Person, serves as trustee for the P. Kent Hawryluk Revocable Trust dated January 25, 2011, which holds 448,277 shares of MBX Biosciences, Inc. Common Stock. This represents an indirect beneficial ownership by the Reporting Person.
Stakeholder Impact
- Shareholders: Increased confidence due to significant insider ownership, suggesting alignment of interests and potential long-term commitment from a key individual.
- Management/Employees: Reinforces the commitment of a key individual within the company, potentially boosting morale and strategic alignment.
Key Dates
| Date | Description |
|---|---|
| 2011-01-25 | Date of P. Kent Hawryluk Revocable Trust establishment. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-03 | Date as of which 44,902,302 shares of Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2025-11-06 | Date of filing of Issuer's Quarterly Report on Form 10-Q. |
| 2025-11-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Recommendation
holdThe filing indicates a significant beneficial ownership by P. Kent Hawryluk, including a substantial portion from exercisable stock options. While this insider stake is generally a positive signal, demonstrating alignment and confidence, a Schedule 13G filing alone does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a notable insider position. Therefore, a 'hold' recommendation is appropriate, pending further analysis of the company's financial performance and strategic developments.
Keywords
MBX Biosciences, P. Kent Hawryluk, Beneficial Ownership, Schedule 13G, Common Stock, Insider Ownership, Stock Options, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.